The fenamate nonsteroidal anti-inflammatory drugs were shown to inhibit the NLRP3 inflammasome and thereby protected against Alzheimer’s disease in rodent models (Daniels et al., 2016). This evidence concerns the gene NLRP3 and early-onset autosomal dominant Alzheimer disease.